modelS02AA13

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:	Miconazole
ATC code:	S02AA13
route:	oral
compartments:	1
dosage:	500	mg
volume of distribution:	1.1	L
clearance:	0.025	L/kg/h
other parameters in model implementation

Miconazole is an imidazole antifungal agent primarily used for treating fungal infections such as candidiasis and dermatophytosis. It is available in various formulations, including topical, oral, and intravenous, but is most commonly used as a topical oropharyngeal formulation. Miconazole is approved and widely used today for local infections.

Pharmacokinetics

Pharmacokinetic parameters estimated for healthy adult subjects using oral administration of miconazole. No published population PK model parameters were available for S02AA13 route; values are based on general estimates from related literature and drug monographs.

References

Simmons, KB, et al., & Merkatz, R (2018). Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception 97(3) 270–276. DOI:10.1016/j.contraception.2017.10.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29097225
Lalla, RV, & Bensadoun, RJ (2011). Miconazole mucoadhesive tablet for oropharyngeal candidiasis. Expert review of anti-infective therapy 9(1) 13–17. DOI:10.1586/eri.10.152 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21171872
Hayashi, Y, et al., & Yamada, Y (1995). [Study of serial bronchoalveolar lavage in patients with aspergilloma: cell reaction at the affected sites and penetration of miconazole and flucytosine into the lesion]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 69(5) 517–523. DOI:10.11150/kansenshogakuzasshi1970.69.517 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7602184

Parameters

Type	Name	Default	Description
Modelica.Units.SI.Mass	weight (from PK_1C)	75	patient weight (kg)
Modelica.Units.SI.SpecificVolume	VdPerKg (from PK_1C)	0.9	Volume of distribution (L/kg)
Modelica.Units.SI.MassFraction	F (from PK_1C)	0.8	bioavailiability (0-1)
Pharmacolibrary.Types.Clearance	Cl (from PK_1C)	20	clearance
Modelica.Units.SI.Time	adminTime (from PK_1C)	60	first administration time (s)
Modelica.Units.SI.Time	adminDuration (from PK_1C)	600	administration duration (s)
Modelica.Units.SI.Time	adminPeriod (from PK_1C)	86060	period of administration (default 8 hours)(s)
Pharmacolibrary.Types.Mass	adminMass (from PK_1C)	1000	administration mass (mg)
Integer	adminCount (from PK_1C)	8	number of dose administered (1)
Pharmacolibrary.Types.Volume	Vd (from PK_1C)	VdPerKg*weight	Volume of distribution (m3)
Pharmacolibrary.Types.MassConcentration	Cmin (from PK_1C)	0.004	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Cmax (from PK_1C)	0.008	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Ctox_peak (from PK_1C)	0.012	toxicity peak level
Pharmacolibrary.Types.MassConcentration	Ctox_trough (from PK_1C)	0.006	toxicity trough level
Pharmacolibrary.Types.TransferRate	ka (from PK_1C_enteral)	0.016666666666666666	first order absorption rate
Modelica.Units.SI.Time	Tlag (from PK_1C_enteral)	600	delay between oral administration and absorption (default 10min)

Connectors

Type	Name	Default	Description
Types.ConcentrationOutput	C_central (from PK_1C)
Interfaces.ConcentrationPort_b	centralCPort (from PK_1C)

Components

Type	Name	Description
Pharmacokinetic.NoPerfusedTissueCompartment	central (from PK_1C)
Pharmacokinetic.ClearanceDrivenElimination	elim (from PK_1C)
Sources.PeriodicDose	periodicDose (from PK_1C)
Modelica.Units.SI.Time	t1_2 (from PK_1C)	elimination half-life

Revisions

06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)